Evaluation of Posaconazole Serum Concentrations Achieved With Delayed-release Tablets and Oral Suspension in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Leonora MuehlbergThomas PabstCarlo LargiadèrYolanda AebiMichael HayozKonrad MuehlethalerStefan ZimmerliCédric HirzelPublished in: Open forum infectious diseases (2024)
Data on posaconazole serum levels of patients on prophylaxis with delayed-release tablets or oral suspension during intensive chemotherapy for acute myeloid leukemia and myelodysplastic syndrome are scarce. In this analysis, the proportion of patients with acute myeloid leukemia/myelodysplastic syndrome achieving posaconazole target concentrations with delayed-release tablets was higher than with oral suspension.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- patients undergoing
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- locally advanced
- peritoneal dialysis
- prognostic factors
- big data
- radiation therapy
- machine learning
- rectal cancer
- chemotherapy induced
- patient reported